Catalyst Biosciences recently announced the initiation and patient enrollment for a phase 2/3, multinational clinical study of marzeptacog alfa (MarzAA), a subcutaneously administered factor VIIa therapy. MarzAA is being developed by Catalyst for the prophylactic treatment of individuals with hemophilia A or B with inhibitors.
Trial investigators will evaluate MarzAA’s ability to “eliminate, or minimize,” spontaneous bleeding episodes in patients. Safety and tolerability of the therapy will also be monitored. According to a Catalyst news release, as many as 12 individuals with hemophilia and an inhibitor will be enrolled, with interim data expected to be announced in the first half of 2018.
“With the initiation of this Phase 2 MarzAA trial, Catalyst is now conducting two clinical studies with subcutaneous candidates for individuals with hemophilia, and we are one step closer to potentially providing safe and convenient treatment options using high potency replacement coagulation factors to restore coagulation.”
Source: Catalyst news release dated January 4, 2018
